# Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection

> **NCT04526717** · PHASE1 · WITHDRAWN · sponsor: **J Ints Bio**

## Conditions studied

- Covid19

## Interventions

- **DRUG:** MPT0B640

## Key facts

- **NCT ID:** NCT04526717
- **Lead sponsor:** J Ints Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was determined not to initiate.
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526717, "Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04526717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*